• Proteoform-Specific Drug Interactions in Native Membranes

  2026-08-23

  The reference study introduces native mass-spectrometric workflows that release membrane-protein complexes directly from retinal rod disc membranes and sequence their individual proteoforms. Its findings show that lipid modifications can control receptor–effector assembly and alter how PDE5 inhibitors engage the off-target retinal phosphodiesterase PDE6, providing a more physiologically relevant framework for drug-selectivity studies.

• Pollen Interference in EEM Hazard Classification

  2026-08-22

  This 2024 Molecules study shows that pollen can distort excitation–emission matrix fluorescence classification of hazardous biological substances, but that feature transformation and random forest modeling can substantially reduce this interference. Fast Fourier transform processing produced the strongest reported improvement, supporting more robust rapid screening of mixed bioaerosol samples while highlighting the need for external validation.

• Leupeptin: Protease Control in TET2 Workflows

  2026-08-21

  Leupeptin, Microbial (Leupeptin hemisulfate) adds reversible control over proteolysis during lysate preparation, autophagy analysis, and antiviral experiments. This guide shows how to use it as a sample-integrity safeguard alongside the TET2 metabolite-binding workflow, without confusing protease protection with direct epigenetic enzyme regulation.

• AS1842856 Foxo1 Inhibitor Guide

  2026-08-20

  AS1842856 is a potent Foxo1 inhibitor that directly binds Foxo1 and reduces its transcriptional activity without lowering Foxo1 expression. Its reported effects on gluconeogenic genes, hepatic glucose production, and autophagy make it a focused tool for metabolic pathway and type 2 diabetes research.

• Triiodothyronine (T3) for Beige Fat Assays

  2026-08-20

  Use Triiodothyronine as a controlled thyroid-hormone input to distinguish receptor-driven metabolic effects from adrenergic beige-fat stimulation. This workflow pairs T3 exposure with SEMA3E perturbation, β-catenin readouts, and mitochondrial respiration to strengthen mechanism-focused metabolic disorder research.

• Shaped ABC Coil-Bottlebrush Terpolymer Self-Assembly

  2026-08-19

  This study examines how sequence-defined bottlebrush shape controls phase behavior in ABC coil–brush–brush terpolymers. Its central finding is that shaping the mutually miscible brush blocks suppresses double-gyroid formation and does not necessarily accelerate ordering, highlighting a distinction between architectural design, phase stability, and assembly kinetics.

• 5-(N,N-dimethyl)-Amiloride: An Assay-Design Guide

  2026-08-19

  5-(N,N-dimethyl)-Amiloride hydrochloride is more than an NHE1 inhibitor: it is a practical perturbation tool for separating ion transport, intracellular pH regulation, and endothelial injury phenotypes. This guide connects DMA pharmacology with assay logic from a moesin-centered sepsis study while clearly distinguishing established evidence from testable hypotheses.

• DiscoveryProbe Natural Product Library Plus for HTS

  2026-08-18

  The DiscoveryProbe Natural Product Library Plus provides 1,655 pre-dissolved natural products for automated HTS and HCS workflows. Its chemical diversity supports natural product screening for drug discovery, while the Cryptosporidium parvum AdhE study supplies a relevant benchmark for hit confirmation rather than direct validation of L1039P.

• CP in EGFR-TKI-Resistant NSCLC

  2026-08-18

  A 2025 study combined network pharmacology, molecular docking, cellular assays, and animal validation to investigate a curcumin–piperlongumine hybrid molecule, CP, in EGFR-TKI-resistant non-small cell lung cancer. The authors report that CP suppresses proliferation through G2/M cell-cycle arrest and apoptosis, with partial involvement of PI3K/AKT signaling, providing a mechanistic framework for further cancer research.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-08-17

  A recent mouse study reports that Thymoquinone reduces doxorubicin-induced cardiac injury, with evidence pointing to Nrf2/HO-1 activation, improved antioxidant defenses, and reduced ferroptosis-associated damage. The findings establish a mechanistic preclinical framework for studying redox stress, mitochondrial injury, and chemotherapy-related cardiotoxicity.

• seRNA-NPCm and the NPM1/c-Myc/NDRG1 Metastatic Axis

  2026-08-17

  A 2023 study identifies carcinogen-induced super-enhancer RNA seRNA-NPCm as a transcriptional driver of nasopharyngeal carcinoma metastasis. Its integrated sequencing, chromatin, perturbation, and patient-tissue analyses connect seRNA-NPCm to NPM1/c-Myc-dependent activation of NDRG1 and support NDRG1 as a prognostic marker.

• CCG-1423: RhoA Inhibitor Workflow Guide

  2026-08-16

  CCG-1423 is a mechanistically distinct RhoA inhibitor for separating MRTF-A nuclear signaling from direct cytoskeletal pathway effects. This guide shows how to apply it in cancer research, apoptosis assay design, and exploratory MVC tight-junction studies while avoiding common solvent, timing, and interpretation errors.

• KCNE4 Shapes Kv1.3 Blocker Pharmacology

  2026-08-15

  The 2024 study shows that the leukocyte ancillary subunit KCNE4 changes the kinetics, but not the apparent affinity, of Psora-4 inhibition of Kv1.3. By comparing an extracellular pore blocker with an intracellular small molecule, the work links channel microarchitecture to pharmacological behavior and highlights why cellular subunit composition matters in Kv1.3-targeted research.

• PPT for ERα Signaling and LUAD Research

  2026-08-15

  PPT enables controlled activation of ERα while minimizing ERβ-driven interpretation, making it useful for receptor-subtype studies and biomarker validation. This workflow connects pharmacological perturbation with the FOXM1–miR-204-5p–ERα network reported in female lung adenocarcinoma research.

• Toremifene in Breast Cancer: Evidence Across 20 Years

  2026-08-14

  This review synthesizes two decades of clinical evidence on toremifene, positioning it as an effective endocrine option for selected postmenopausal patients with hormone receptor–positive breast cancer. Its main contribution is the integrated comparison of efficacy, safety, pharmacokinetics, CYP2D6-related metabolism, and the therapeutic distinctions between selective estrogen receptor modulators and aromatase inhibitors.

451 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page